Federal health officials warned Thursday that there was a significant risk the mpox virus will resurge this summer and reiterated calls for people at high risk to get vaccinated if they have not already done so.
The warnings came after a cluster of 21 mpox cases were identified in Chicago this month, one of the first major clusters since the outbreak in the U.S. died down last fall, and as three different estimates of the mpox vaccine’s effectiveness were published Thursday afternoon.
Although the methods and precise findings of those studies varied, they collectively showed that two doses of the vaccine, known as Jynneos, were effective at preventing symptomatic disease. The vaccine is made by Danish manufacturer Bavarian Nordic.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect